Trials / Completed
CompletedNCT01546415
Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desferasirox | Initial Dose: 20 mg/kg/d. Dose modification according to protocol. |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2012-03-07
- Last updated
- 2014-10-28
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01546415. Inclusion in this directory is not an endorsement.